Ipamorelin vs Other GH Peptides: Research Compared

Ipamorelin vs Other GH Peptides: Research Compared Peer-reviewed analysis of ipamorelin receptor selectivity, endocrine specificity, and GHSR-1a signaling in preclinical models. The question of how research “compares” ipamorelin with other growth hormone peptides carries a quiet assumption worth surfacing before we start: that there exists a mature, head-to-head body of evidence ranking these compounds against one another on clinical outcomes that matter to people. That is not the situation. Ipamorelin and its cousins — GHRP-2, GHRP-6, hexarelin, sermorelin, CJC-1295, tesamorelin, MK-677 — occupy wildly different evidence tiers, from a single FDA-approved indication in one case to nothing but rodent pharmacology in another. A fair comparison, then, is not a leaderboard of efficacy but a map of what each molecule was designed to do, what receptor it hits, and how far each has actually traveled through the evidence pipeline. Ipamorelin’s claim to distinction is narrow and specific, and it is a pharmacological one, not a therapeutic one.1 So this article treats the comparison as an honest exercise in classification and mechanism rather than a ranking of proven benefits. Ipamorelin is a synthetic growth hormone secretagogue — a ghrelin-receptor agonist — that is not approved by the U.S. Food and Drug Administration or any comparable regulator for any indication. Its most celebrated property, the selectivity that earned it the label “the first selective growth hormone secretagogue,” is real and was demonstrated in careful preclinical work.1 But selectivity is a property of the molecule’s receptor pharmacology, not evidence that it treats, prevents, or reverses any disease. The one time ipamorelin was tested in a controlled human trial for a defined clinical endpoint, it failed.4 Holding both of those facts in view at once — elegant pharmacology, thin clinical record — is the whole discipline of writing about this compound honestly. What follows is a structured tour: how the growth hormone axis works and why there are two distinct “doors” into it; what specifically makes ipamorelin different from the other ghrelin mimetics; how it sits against the GHRH-analog class (sermorelin, CJC-1295, tesamorelin) that works through an entirely different receptor; where the oral agent MK-677 fits; why full-length recombinant human growth hormone remains the reference standard all of these are implicitly measured against; and, throughout, an unflinching accounting of the evidence level behind each claim. The guiding rule is restraint: where the data are rodent-only, we will say so; where a human trial exists, we will report what it actually found, including when that was disappointing. To compare growth hormone peptides intelligently, you first have to understand that the pituitary’s release of growth hormone (GH) is governed by a push-pull system with two accelerators and one brake. The two accelerators are growth hormone-releasing hormone (GHRH), secreted by the hypothalamus, and ghrelin, the acylated peptide discovered in 1999 that is produced mainly in the stomach and is the endogenous ligand for the growth hormone secretagogue receptor.8 The brake is somatostatin, which tonically suppresses GH release. Endogenous GH is not secreted in a steady trickle; it comes out in pulses, sculpted by the interplay of these three signals across the day and night.9 This matters because the peptides marketed as “GH peptides” fall into two mechanistically distinct families defined by which door they open. The first family, the GHRH analogs — sermorelin, CJC-1295, and tesamorelin — bind the GHRH receptor on pituitary somatotrophs and mimic the hypothalamic releasing signal. The second family, the growth hormone secretagogues (GHS) or ghrelin mimetics — ipamorelin, GHRP-2, GHRP-6, hexarelin, and the orally active MK-677 — bind the growth hormone secretagogue receptor, GHS-R1a, the same seven-transmembrane G-protein-coupled receptor that ghrelin activates.11 Ipamorelin belongs squarely to this second family. Its selectivity for the GHS-R1a receptor and its downstream signaling are the subject of a dedicated companion analysis on which studies demonstrate ipamorelin’s precision in targeting the GHSR-1a receptor, and understanding that receptor selectivity is the key to understanding why ipamorelin behaves differently from the other members of its own class. The GHS-R1a agonists do something the GHRH analogs cannot: they can help initiate a GH pulse rather than merely amplifying an existing one, and they appear to work in part by functionally antagonizing somatostatin’s inhibitory tone while also acting directly on the somatotroph.9 Ghrelin and its mimetics act at both the hypothalamic and pituitary levels, and their full GH-releasing effect in vivo depends on an intact endogenous GHRH system — the two pathways are physiologically intertwined even though they are pharmacologically separate.9 This dual-door architecture is the single most important concept for the comparisons that follow, because it explains both why a GHRH analog and a GHRP are so often combined and why comparing ipamorelin to tesamorelin is a bit like comparing two keys that fit different locks in the same house. It also helps to remember what GH itself is a proxy for. Most of GH’s durable anabolic and metabolic effects are mediated by insulin-like growth factor 1 (IGF-1), produced largely in the liver in response to GH and circulating with a far longer half-life than GH’s minutes-long pulses. IGF-1 is therefore the variable that sustained-action agents (CJC-1295 with DAC, MK-677) tend to push up around the clock, whereas short-acting pulse agents like ipamorelin, sermorelin, Ipamorelin’s identity is best understood against the history of the compounds that came before it. The growth hormone-releasing peptide story began in the 1970s and 1980s with Cyril Bowers’ work on enkephalin-derived peptides that selectively promoted GH secretion, leading to GHRP-6 and later GHRP-2.7 These early GHRPs were potent GH releasers, but they carried a nuisance: at GH-releasing doses they also nudged up other pituitary hormones, notably adrenocorticotropic hormone (ACTH) and cortisol, and to varying degrees prolactin.1 That lack of specificity limited their appeal as clean research tools for isolating GH biology. Ipamorelin was the answer to that problem. Described by Raun and colleagues at Novo Nordisk in 1998, it is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂, identified within a series of compounds built by removing the central Ala-Trp dipeptide of GHRP-1.1 In conscious swine, ipamorelin released GH with a potency and maximal effect closely matching GHRP-6 (ED₅₀ of roughly 2–4 nmol/kg for both), confirming it was a genuine, full-efficacy GH secretagogue.1 The breakthrough was what it did not do. Pharmacological profiling with GHRP and GHRH antagonists showed ipamorelin releases GH through a GHRP-like (ghrelin) receptor, yet it did not raise ACTH or cortisol above the levels seen with GHRH alone — and it did so with a selectivity margin exceeding 200-fold the ED₅₀ for GH release, a separation not previously reported for any GHRP-receptor agonist.1 None of the secretagogues tested altered FSH, LH, prolactin, or TSH, but only ipamorelin also spared ACTH and cortisol.1 That is the entire basis of the “selective” label, and it is worth stating precisely what it means and does not mean. It means that, in these preclinical assays, ipamorelin could drive a robust GH pulse without meaningfully co-stimulating the adrenal (cortisol) or lactotroph (prolactin) axes. It does not mean ipamorelin is more effective than other GHRPs at anything a patient would care about; both released comparable GH. Selectivity is a cleanliness property, prized because it makes ipamorelin a better probe for studying GH in isolation and, in principle, a candidate with fewer off-target endocrine effects. Whether that cleaner profile translates into any clinical advantage has never been established, because ipamorelin’s clinical program is essentially a single failed trial, discussed below. For readers cataloging where ipamorelin sits among related compounds, the site’s central dosage index organizes these secretagogues by class for educational reference. The structure-activity story behind that selectivity is instructive. Ipamorelin was found within a series designed by stripping the central Ala-Trp dipeptide out of GHRP-1, a deliberate exploration of which residues drive GH release versus which drive the unwanted ACTH and prolactin co-stimulation.1 The resulting pentapeptide retained the GH-releasing pharmacophore while shedding the structural features that recruit The fairest and most direct comparison is within ipamorelin’s own class, because these compounds share the GHS-R1a target and differ mainly in selectivity, potency, and secondary effects. All are ghrelin mimetics; all can initiate GH pulses; none is FDA-approved for a body-composition or anti-aging indication. GHRP-6 is the archetype — potent at GH release but also a notable stimulator of appetite (a direct consequence of ghrelin-receptor agonism) and a mild inducer of cortisol and prolactin.1 GHRP-2 is more potent than GHRP-6 as a GH releaser but produces a similar, dose-dependent bump in ACTH and cortisol.1 Hexarelin is among the most potent of the group and has been studied for direct cardiovascular actions via CD36 and GHS receptors, but it too elevates cortisol and prolactin and is prone to receptor desensitization with repeated dosing. Against this backdrop, ipamorelin’s distinguishing feature is not raw potency — GHRP-2 and hexarelin can out-release it — but the clean endocrine profile documented by Raun and colleagues.1 Ipamorelin GHS-R1a (ghrelin) Comparable to GHRP-61 Not raised above GHRH-alone in preclinical work1 Minimal prolactin change; modest appetite signal One failed phase 2 human RCT (ileus)4 GHRP-6 Reference potent GHRP1 Mild increase1 Strong appetite stimulation Preclinical + human GH-provocation use GHRP-2 Higher than GHRP-6 Dose-dependent increase1 Appetite; used as diagnostic GH stimulus Human GH-stimulation testing (some regions) Hexarelin GHS-R1a + CD36 Very high Increase; also prolactin Direct cardiac actions studied; tachyphylaxis Preclinical + small human studies The pattern is clear. Ipamorelin trades a small amount of the raw punch that GHRP-2 or hexarelin offer for a much cleaner hormonal signature. For a researcher who wants to study GH pulsatility without confounding the picture with a cortisol surge, that trade is attractive; it is the reason ipamorelin is so frequently the GHRP of choice in mechanistic work and in the exploratory combination protocols catalogued under GH-peptide research. But it is essential to see the limit of the table’s rightmost column: not one of these compounds has a robust, positive, controlled human trial for muscle, fat loss, recovery, or longevity. Their “evidence tier” is dominated by animal pharmacology and, in a couple of cases, use as a short-term diagnostic GH-provocation agent — not as a therapy. A second axis of difference within the family is the tendency toward receptor desensitization, or tachyphylaxis. Hexarelin in particular is known to blunt its own response with frequent repeated dosing, as the GHS-R1a receptor down-regulates — a property that complicates any sustained-use strategy. Ipamorelin and the other short-acting GHRPs are generally described as producing reproducible pulses when dosing is spaced, which is part of why pulsatile, spaced administration is the norm in research use rather than continuous exposure. This is a mechanistic distinction with practical impli Comparing ipamorelin to the GHRH analogs is comparing across the two doors of the GH axis, and it produces the single most important asymmetry in this whole landscape: the GHRH-analog class contains the only FDA-approved member of the entire GH-peptide family, while the GHS class contains none. Sermorelin is the native GHRH(1–29) fragment, the minimal sequence that retains full GHRH activity. It has a very short plasma half-life (on the order of minutes) and was historically marketed for diagnostic testing of GH secretion and for pediatric GH deficiency before being withdrawn in that branded form for commercial rather than safety reasons. It is now widely discussed as a research secretagogue; the evidence for its role in stimulating endogenous GH is reviewed in the site’s piece on what research says about sermorelin’s role in stimulating natural growth hormone, and its more speculative neurocognitive angle in the discussion of whether sermorelin supports cognitive function in age-related neurodegeneration. CJC-1295 is a modified GHRH analog engineered for stability; in its DAC (drug affinity complex) form it binds albumin and extends the functional half-life dramatically, producing a sustained elevation in GH and IGF-1 rather than discrete pulses. This is pharmacologically interesting but introduces its own concern: a continuous, non-pulsatile IGF-1 elevation departs from normal physiology in a way that discrete-pulse agents like ipamorelin do not. CJC-1295 is not FDA-approved and its human evidence base is thin. Tesamorelin is the outlier and the benchmark. It is a stabilized GHRH analog that the FDA approved in 2010 (brand name Egrifta) for one specific indication: reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. That approval rests on a genuine pivotal program — the phase 3 trial reported by Falutz and colleagues in the New England Journal of Medicine randomized 412 patients with HIV and abdominal fat accumulation to 2 mg daily tesamorelin or placebo for 26 weeks, and demonstrated a statistically significant, CT-measured reduction in visceral fat of roughly 15% versus placebo.5 That is real, regulator-grade evidence for a defined population and endpoint. It is also worth stating its limits plainly: the effect is specific to visceral fat in that population, it reverses on discontinuation, and it does not license claims about tesamorelin — let alone ipamorelin — for general fat loss, muscle building, or anti-aging. GHS / ghrelin mimetic GHS-R1a Pulsatile (short action) Not FDA-approved for any use1 Sermorelin GHRH analog GHRH receptor Pulsatile (very short) Prior diagnostic/pediatric approval withdrawn; not currently approved as marketed drug CJC-1295 (DAC) Sustained (long half-life) Not FDA-approved Tesamorelin Pulsatile (short) FDA-approved for HIV-associated lipodystrophy5 MK-677 (ibutamoren) Sustained (oral, long action) Not FDA-approved; investigational The comparison delivers a sobering perspective o MK-677, or ibutamoren, deserves separate treatment because it shares ipamorelin’s receptor (GHS-R1a) but differs in two consequential ways: it is orally active and non-peptidic, and it has a long duration of action that produces sustained rather than sharply pulsatile GH/IGF-1 elevation. Crucially, MK-677 also has something ipamorelin lacks — a substantial, long-duration randomized human trial. Nass and colleagues conducted a two-year, double-blind, randomized, placebo-controlled trial of once-daily oral MK-677 (25 mg) in healthy older adults. The compound restored GH and IGF-1 levels toward those of healthy young adults, and increased fat-free mass by about 1.6 kg relative to placebo over the first year.6 That is a real, controlled human demonstration that a GHS-R1a agonist can shift body composition. But the same trial delivered the essential caveat: the increase in fat-free mass was attributable largely to intracellular water (body cell mass) rather than clearly demonstrated functional muscle gains, and some participants showed increased fasting glucose and reduced insulin sensitivity — a predictable consequence of sustained GH/IGF-1 elevation.6 It is worth dwelling on the “fat-free mass is mostly water” finding, because it is one of the most honest and most often ignored results in the entire GH-peptide literature. Fat-free mass measured by common methods includes intracellular and extracellular water, and GH/IGF-1 elevation is well known to cause fluid retention. When Nass and colleagues examined the composition of the gain, the increase tracked with body cell water rather than with an unambiguous rise in contractile muscle, and the trial did not show a corresponding improvement in the functional endpoints (such as strength or physical performance) that would confirm a meaningful muscle effect.6 This is the recurring lesson of GH-axis interventions across the board: a number on a body-composition scan can move without the outcome a person actually wants moving with it. Any comparison that cites “increased lean mass” for a GH peptide without asking whether that mass was water or function is repeating a half-truth. The MK-677 data are the closest thing the ghrelin-mimetic class has to a rigorous long-term human read-out, and they are instructive precisely because they are mixed: a measurable body-composition signal accompanied by a metabolic cost and no demonstrated hard-outcome benefit. For ipamorelin, the implication is twofold. First, it is biologically plausible that ipamorelin could produce similar body-composition shifts, since it hits the same receptor. Second, and more importantly, that has not been shown for ipamorelin, and MK-677’s glucose signal is a caution that even within this class, activating the ghrelin receptor chronically is not consequence-free. Extrapolating MK-677’s human data onto ipamorelin is a hypothesis, not a finding — ipamorelin’s much shorter action and pulsatile profile could plausibly produce a different metabol Every secretagogue in this article is, implicitly or explicitly, compared to the thing it aims to stimulate: growth hormone itself. Recombinant human GH (somatropin) is FDA-approved for genuine indications — pediatric and adult GH deficiency, Turner syndrome, chronic kidney disease in children, short bowel syndrome, and HIV-associated wasting, among others — and its efficacy in those settings is well established. It is the reference standard, and understanding it clarifies both the appeal and the limits of the peptide approach. The theoretical argument for secretagogues over direct GH is physiological fidelity. Injecting recombinant GH produces a supraphysiological spike and bypasses the pituitary’s feedback control; a secretagogue like ipamorelin instead prompts the pituitary to release its own GH in a pulse shaped by the body’s remaining regulatory machinery, and it cannot override the negative feedback that IGF-1 and somatostatin impose.9 In principle this ceiling could translate into a lower risk of the classic GH excess effects — edema, joint pain, carpal tunnel, insulin resistance — that accompany exogenous GH. In principle. The honest counterpoint is that “more physiological” has not been shown to mean “as effective” or even “clearly safer” for ipamorelin, because the comparative trials do not exist. Recombinant GH earns its indications through decades of controlled data; ipamorelin earns nothing comparable. A researcher exploring GH biology might reasonably prefer a secretagogue as a tool because it works with the body’s own release machinery, and the exploratory combination approaches often discussed in the context of the grow-H blend and whether it truly boosts strength and repair lean on exactly that rationale. But rationale is not proof, and the appropriate framing is that ipamorelin is a mechanistically interesting stimulator of endogenous GH whose clinical equivalence or superiority to approved GH therapy is entirely unestablished. One of the most consistent findings across GH-secretagogue pharmacology — and one of the clearest ways ipamorelin is used in practice — is the synergy between the two doors. When a GHRH analog and a GHRP are given together, the combined GH release substantially exceeds the sum of each given alone, an observation traceable to Bowers’ classic work and reproduced across species.7 The mechanistic explanation follows directly from the axis architecture: the GHRH analog pushes on the GHRH receptor while the GHRP pushes on the GHS-R1a receptor and simultaneously relieves somatostatin’s brake, so two independent stimulatory inputs converge on the somatotroph while the inhibitory input is withdrawn.9 This is why ipamorelin is so frequently paired with a GHRH analog such as CJC-1295 in research protocols: the ghrelin-mimetic arm provides the pulse-initiating, somatostatin-antagonizing signal, and the GHRH arm amplifies it. Ipamorelin’s selectivity makes it a particularly logical partner, because it contributes its share of the GH stimulus without adding the cortisol and prolactin noise that GHRP-2 or hexarelin would bring to the same combination.1 It is worth making the mechanism concrete. Somatostatin sets the “trough” between GH pulses; GHRH sets the height of a pulse when the trough lifts. A ghrelin mimetic like ipamorelin does two things at once — it adds its own stimulatory drive at the somatotroph and it functionally opposes somatostatin’s suppression, effectively lowering the trough so a GHRH-driven pulse can rise higher.9 Give GHRH into a suppressed system and you get a modest pulse; give it into a system where somatostatin has been withdrawn by a GHRP, and the same GHRH signal produces a much larger pulse. That is the physiological logic of the observed better-than-additive response, and it is why the pairing recurs so consistently across the literature rather than being a quirk of one study.7 Two honesty caveats are essential here. First, the synergy is well demonstrated for the acute GH-release endpoint — put the two together and you measure more GH. It is not demonstrated that this larger GH pulse produces any superior clinical outcome, because those downstream trials have not been done for ipamorelin-containing combinations. Second, not all pairings are synergistic: combining two GHRH analogs, or in some cases layering a sustained-release ghrelin mimetic like MK-677 onto a GHRH analog, can produce competition or blunting rather than synergy, because they crowd the same receptor or drive the axis into feedback suppression. The clean synergy story applies specifically to the GHRH-plus-GHRP pairing, and even there it is a story about hormone levels in the blood, not about proven benefit in a body. Here the comparison must confront ipamorelin’s thinnest dimension directly. Despite two decades of enthusiastic secondary writing, ipamorelin’s own clinical record consists essentially of preclinical pharmacology plus a single, negative human efficacy trial. The preclinical file is genuinely solid for what it is. Beyond the foundational selectivity work,1 ipamorelin was shown in rats to induce longitudinal bone growth — Johansen and colleagues demonstrated dose-dependent increases in bone growth rate and body weight with subcutaneous ipamorelin.2 Svensson and colleagues reported that ipamorelin, like GHRP-6, increased bone mineral content in adult female rats over a 12-week course.3 These are legitimate, peer-reviewed animal findings consistent with a functioning GH secretagogue. But they are rodent data on bone and body weight, not human data on any clinical outcome. The one time ipamorelin entered a controlled human trial for a defined therapeutic endpoint, the result was negative. Beck, Sweeney, and McCarter, on behalf of the Ipamorelin 201 Study Group, ran a prospective, randomized, controlled phase 2 proof-of-concept study of intravenous ipamorelin for the management of postoperative ileus — the temporary gut paralysis after bowel-resection surgery — reasoning that a ghrelin mimetic might promote gastrointestinal motility.4 The trial did not meet its primary efficacy endpoint, and the ipamorelin development program for that indication was discontinued.4 This is the highest-quality human evidence that exists specifically for ipamorelin, and it is a null result. The postoperative-ileus choice of indication is itself revealing about how these compounds reach the clinic. Ghrelin and its mimetics are prokinetic — they promote gastrointestinal motility — so testing ipamorelin in the post-surgical gut was a mechanistically reasonable bet, arguably more grounded than the body-composition claims that dominate popular discussion. That even a biologically sensible, properly randomized trial came back negative is a cautionary tale about the gap between plausible mechanism and demonstrated effect. It is the same lesson that recurs throughout translational medicine: a compound can do exactly what its pharmacology predicts at the level of receptors and hormones and still fail to move a clinical endpoint, because human physiology has more moving parts than any single pathway. Ipamorelin’s one clean shot on goal missed, and the program stopped there.4 The comparative takeaway is stark and should not be softened. Among the peptides in this article, ipamorelin has arguably the most elegant receptor pharmacology and one of the thinnest clinical records: strong rodent data, one failed human trial, and no controlled human evidence for the body-composition, recovery, or anti-aging uses for which it is popularly discussed. Contrast this with tesamorelin’s 412-patient approval trial5 and MK-677’s two-year randomized study,6 and ipamorelin’s position becomes clear: i Pulling the strands together, it helps to score each compound on two independent axes that popular writing tends to conflate: mechanistic elegance (how clean and well-characterized its pharmacology is) and clinical evidence (how far it has traveled through controlled human testing). Ipamorelin scores high on the first and low on the second — a dissociation that is the central, honest message of any comparison. Excellent — defined selectivity, GHS-R1a agonist1 One negative phase 2 trial (ileus)4 No Clean pharmacology, essentially no positive human efficacy data GHRP-2 / GHRP-6 Good — potent GHRPs, less selective1 Used in GH-stimulation testing No (varies by region) Co-stimulate ACTH/cortisol; appetite effects Good — potent, dual GHS-R1a/CD36 Small human studies Tachyphylaxis; cortisol/prolactin Good — native GHRH(1–29) Historical diagnostic/pediatric use Withdrawn branded form Very short half-life; limited modern trials Good — long-acting GHRH analog Small PK/GH studies Non-pulsatile IGF-1 elevation departs from physiology Excellent — stabilized GHRH analog Phase 3 RCT, n=4125 Yes (HIV lipodystrophy) Benefit narrow, visceral-fat-specific, reverses on stopping MK-677 Excellent — oral GHS-R1a agonist 2-year RCT, older adults6 FFM gain largely water; raises glucose/insulin resistance Read down the “approved indication” column and the landscape resolves into focus: one yes, everything else no. Read across ipamorelin’s row and the compound’s honest identity emerges: a beautifully characterized molecule that has never been shown to help a human with anything. Those two facts are not in tension; they are simply what the evidence says, and any comparison that lets the first fact imply the second has crossed from science into salesmanship. Comparative safety is where ipamorelin’s selectivity earns its most defensible — but still limited — distinction. Because ipamorelin does not meaningfully co-stimulate ACTH, cortisol, or prolactin in preclinical work,1 it avoids the specific off-target endocrine effects that make GHRP-2, GHRP-6, and hexarelin messier as research tools. In principle this narrower footprint could translate into fewer such effects in humans. In principle. Several caveats keep this from becoming a clean safety claim. First, the selectivity data are preclinical; ipamorelin’s human safety over meaningful durations is uncharacterized, since its only controlled human exposure was short-term intravenous dosing in a surgical trial.4 Second, every GHS-R1a agonist shares the ghrelin receptor’s intrinsic effects — appetite stimulation and, with sustained activation, the potential for the glucose and insulin-sensitivity shifts seen clearly with MK-677.6 Ipamorelin’s short, pulsatile action may blunt those metabolic effects relative to long-acting MK-677, but this is inference, not measured fact. Third — and this applies across the entire class — any intervention that chronically elevates GH and IGF-1 raises the theoretical, unquantified questions that always attach to the GH/IGF-1 axis, including effects on glucose metabolism and on tissues sensitive to growth signaling. These concerns are not established harms for ipamorelin; they are open questions that the absence of long-term human data leaves unanswered. A final, non-pharmacological safety dimension separates these compounds sharply and is easy to overlook: product provenance. Tesamorelin, as an approved drug, is manufactured to pharmaceutical standards. The research-grade GHRPs, ipamorelin included, circulate largely through channels that are not subject to that oversight, so purity, correct identity, and freedom from endotoxin vary and are frequently unverified. This is a risk that has nothing to do with the molecule’s intrinsic pharmacology and everything to do with sourcing, and it arguably dominates the practical safety comparison for the non-approved members of this family. Standard research handling — reconstitution technique, storage, and stability — is common across the peptide class and is covered in the general peptide reconstitution guide; careful handling preserves whatever activity a compound has but cannot compensate for uncertain source material or absent efficacy data. Regulatory posture is the dimension where the comparison is least ambiguous, and it deserves a clear statement because marketing language routinely blurs it. Ipamorelin is not approved by the FDA, the European Medicines Agency, or any comparable regulator for any therapeutic indication. Its development as a treatment for post